Citations

Clear

4847 citation(s) found for "Yu, Eric".

The genetic determinants of recurrent somatic mutations in 43,693 blood genomes
Weinstock, Joshua S. , Laurie, Cecelia , Broome, Jai , Taylor, Kent D. , Guo, Xiuqing , Shuldiner, Alan R. , O’Connell, Jeffrey R. , Lewis, Joshua P. , Boerwinkle, Eric , Barnes, Kathleen C. , Chami, Nathalie , Loos, Ruth J. F. , Fornage, Myriam , Redline, Susan , Cade, Brian E. , Chen, Zhanghua , Gauderman, W. James , Schleimer, Robert P. , Bis, Joshua C. , Brody, Jennifer A. , Silverman, Edwin K. , Qiao, Dandi , Lasky‐Su, Jessica , DeMeo, Dawn L. , Palmer, Nicholette D. , Bowden, Donald W. , Johnson, Andrew D. , Yanek, Lisa R. , Becker, Lewis C. , Kardia, Sharon L.R., Kaplan, Robert C. , Heckbert, Susan R. , Smith, Nicholas L. , Arnett, Donna K. , Irvin, Marguerite R. , Tiwari, Hemant K., Raffield, Laura M. , Gao, Yan , Rotter, Jerome I. , Wheeler, Marsha M. , Duggirala, Ravindranath , Xiao, Shujie, Williams, L. Keoki , Meyers, Deborah A. , Ortega, Victor E. , McGarvey, Stephen T. , Chen, Yii‐Der Ida , Lee, Wen‐Jane , Shoemaker, M. Benjamin , Roden, Dan M. , Blackwell, Thomas W. , Smith, Albert V. , Kang, Hyun Min , Mathias, Rasika A. , Natarajan, Pradeep , Jaiswal, Siddhartha , Reiner, Alex P. , Bick, Alexander G. , Kaplan, Robert C. , Broome, Jai , Kenny, Eimear E , Loos, Ruth J F , Fornage, Myriam , Redline, Susan , Cade, Brian E , Gauderman, W James , Grammer, Leslie , Schleimer, Robert P , Bis, Joshua C , Brody, Jennifer A , Silverman, Edwin K , Yun, Jeong H , Qiao, Dandi , Weiss, Scott T , Palmer, Nicholette D , Freedman, Barry I , Cho, Michael H , Vasan, Ramachandran S , Johnson, Andrew D , Yanek, Lisa R , Becker, Lewis C , He, Jiang , Heckbert, Susan R , Wiggins, Kerri L , Arnett, Donna K , Correa, Adolfo , Raffield, Laura M , Gao, Yan , Rotter, Jerome I , Rich, Stephen S , Manichaikul, Ani W , Konkle, Barbara A , Johnsen, Jill M , Custer, Brian S , Duggirala, Ravindranath , Curran, Joanne E , Li, Xingnan , McGarvey, Stephen T , Gu, C Charles , Lee, Wen-Jane , Darbar, Dawood , Roden, Dan M. , Kooperberg, Charles , Desai, Pinkal M , Smith, Albert V , Kang, Hyun M , Mathias, Rasika A , Natarajan, Pradeep , Jaiswal, Siddhartha , Bick, Alexander G , Weinstock, Joshua S , Shuldiner, Alan R , Taylor, Kent D , Guo, Xiuqing , Lasky-Su, Jessica , Gilliland, Frank D. , Kumar, Rajesh , Psaty, Bruce M. , Yun, Jeong H. , Weiss, Scott T. , Freedman, Barry I. , Cho, Michael H. , Vasan, Ramachandran S. , He, Jiang , Wiggins, Kerri L. , Andrade, Mariza de , Rich, Stephen S. , Manichaikul, Ani , Konkle, Barbara A. , Custer, Brian , Curran, Joanne E. , Blangero, John , Gui, Hongsheng , Li, Xingnan , Darbar, Dawood , Albert, Christine M. , Kooperberg, Charles , Desai, Pinkal , Abecasis, Gonçalo R.

Mayo Clinic

Science Advances | April 26, 2023 | Volume: 9 | Issue: 17 | Pages: No page available

10.1126/sciadv.abm4945 | PMID 37126548 Get It

Nononcogenic somatic mutations are thought to be uncommon and inconsequential. To test this, we analyzed 43,693 National Heart, Lung and Blood Institute Trans-Omics for Precision Medicine blood whole genomes from 37 cohorts and identified 7131 non-missense somatic mutations that are recurrently mutated in at least 50 individuals. These recurrent non-missense somatic mutations (RNMSMs) are not clearly explained by other clonal phenomena such as clonal hematopoiesis. RNMSM prevalence increased with age, with an average 50-year-old having 27 RNMSMs. Inherited germline variation associated with RNMSM acquisition. These variants were found in genes involved in adaptive immune function, proinflammatory cytokine production, and lymphoid lineage commitment. In addition, the presence of eight specific RNMSMs associated with blood cell traits at effect sizes comparable to Mendelian genetic mutations. Overall, we found that somatic mutations in blood are an unexpectedly common phenomenon with ancestry-specific determinants and human health consequences.
Multiorganizational consensus to define guiding principles for perioperative pain management in patients with chronic pain, preoperative opioid tolerance, or substance use disorder
Dickerson, David , Mariano, Edward R. , Szokol, Joseph W., Harned, Michael , Clark, Randall M, Mueller, Jeffrey T. , Shilling, Ashley , Udoji, Mercy A. , Mukkamala, S Bobby, Doan, Lisa , Wyatt, Karla , Elkassabany, Nabil , Beck, Stacy , Wiechmann, Lisa, Chiao, Franklin, Halle, Steven G, Krishnan, Deepak G. , Cramer, John D. , Esa, Wael Ali Sakr, Muse, Iyabo O. , Baratta, Jaime L., Rosenquist, Richard W. , Gulur, Padma, Shah, Shalini , Kohan, Lynn , Robles, Jennifer, Yang, Stephen C. , Hadeed, Josef G., Schwartz, Gary , Sprintz, Michael, Urish, Kenneth L. , Walton, Ashley , Keith, Lauren, Buvanendran, Asokumar , Dickerson, David M , Muse, Iyabo O , Rosenquist, Richard , Schwenk, Eric S , Schwartz, Gary , Mariano, Edward R , Clark, Randall M., Schwalb, Jason M. , Eloy, Jean Daniel , Schwenk, Eric S. , Allen, Brian F.S. , Englesbe, Michael J. , Walton, Ashley, Keith, Lauren

Mayo Clinic

Regional Anesthesia & Pain Medicine | April 25, 2023 | Volume: 49 | Issue: 10 | Pages: 716-724

10.1136/rapm-2023-104435 | PMID 37185214 Get It

Significant knowledge gaps exist in the perioperative pain management of patients with a history of chronic pain, substance use disorder, and/or opioid tolerance as highlighted in the US Health and Human Services Pain Management Best Practices Inter-Agency Task Force 2019 report. The report emphasized the challenges of caring for these populations and the need for multidisciplinary care and a comprehensive approach. Such care requires stakeholder alignment across multiple specialties and care settings. With the intention of codifying this alignment into a reliable and efficient processes, a consortium of 15 professional healthcare societies was convened in a year-long modified Delphi consensus process and summit. This process produced seven guiding principles for the perioperative care of patients with chronic pain, substance use disorder, and/or preoperative opioid tolerance. These principles provide a framework and direction for future improvement in the optimization and care of ‘complex’ patients as they undergo surgical procedures.
Serially measured high-sensitivity cardiac troponin T, N-terminal-pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and growth differentiation factor 15 for risk assessment after acute coronary syndrome: the BIOMArCS cohort
Gürgöze, Muhammed T. , Akkerhuis, K. Martijn , Umans, Victor A. , Kietselaer, Bas , Schotborgh, Carl E. , Lenderink, Timo , Aksoy, Ismail , Harst, Pim van der , Asselbergs, Folkert W. , Maas, Arthur , Ophuis, Anton J. Oude, Krenning, Boudewijn J., Winter, Robbert J. de , The, Salem H.K., Wardeh, Alexander J. , Hermans, Walter, Cramer, G. Etienne , Gorp, Ina van, Schaik, Ron H. N. van , Boersma, Eric , Lenderink, Timo , Boersma, Eric , van der Harst, Pim , Kietselaer, Bas L J H , Oemrawsingh, Rohit M. , Ronner, Eelko , de Rijke, Yolanda B

Mayo Clinic

European Heart Journal: Acute Cardiovascular Care | April 25, 2023 | Volume: 12 | Issue: 7 | Pages: 451-461

10.1093/ehjacc/zuad042 | PMID 37096818 Get It

Abstract Aims Evidence regarding the role of serial measurements of biomarkers for risk assessment in post-acute coronary syndrome (ACS) patients is limited. The aim was to explore the prognostic value of four, serially measured biomarkers in a large, real-world cohort of post-ACS patients. Methods and results BIOMArCS is a prospective, multi-centre, observational study in 844 post-ACS patients in whom 12 218 blood samples (median 17 per patient) were obtained during 1-year follow-up. The longitudinal patterns of high-sensitivity cardiac troponin T (hs-cTnT), N-terminal-pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity C-reactive protein (hs-CRP), and growth differentiation factor 15 (GDF-15) were analysed in relation to the primary endpoint (PE) of cardiovascular mortality and recurrent ACS using multivariable joint models. Median age was 63 years, 78% were men and the PE was reached by 45 patients. The average biomarker levels were systematically higher in PE compared with PE-free patients. After adjustment for 6-month post-discharge Global Registry of Acute Coronary Events score, 1 standard deviation increase in log[hs-cTnT] was associated with a 61% increased risk of the PE [hazard ratio (HR) 1.61, 95% confidence interval (CI) 1.02–2.44, P = 0.045], while for log[GDF-15] this was 81% (HR 1.81, 95% CI 1.28–2.70, P = 0.001). These associations remained significant after multivariable adjustment, while NT-proBNP and hs-CRP were not. Furthermore, GDF-15 level showed an increasing trend prior to the PE (Structured Graphical Abstract). Conclusion Longitudinally measured hs-cTnT and GDF-15 concentrations provide prognostic value in the risk assessment of clinically stabilized patients post-ACS. Clinical Trial Registration The Netherlands Trial Register. Currently available at URL https://trialsearch.who.int/; Unique Identifiers: NTR1698 and NTR1106.
National trends in prescription drug expenditures and projections for 2023
Tichy, Eric M. , Hoffman, James M. , Tadrous, Mina , Rim, Matthew H, Suda, Katie J. , Cuéllar, Sandra , Clark, John Spencer , Newell, Mary Kate, Schumock, Glen T.

Mayo Clinic

American Journal of Health-System Pharmacy | April 24, 2023 | Volume: 80 | Issue: 14 | Pages: 899-913

10.1093/ajhp/zxad086 | PMID 37094296 Get It

Abstract Purpose To report historical patterns of pharmaceutical expenditures, to identify factors that may influence future spending, and to predict growth in drug spending in 2023 in the United States, with a focus on the nonfederal hospital and clinic sectors. Methods Historical patterns were assessed by examining data on drug purchases from manufacturers using the IQVIA National Sales Perspectives database. Factors that may influence drug spending in hospitals and clinics in 2023 were reviewed, including new drug approvals, patent expirations, and potential new policies or legislation. Focused analyses were conducted for biosimilars, cancer drugs, diabetes medications, generics, COVID-19 pandemic influence, and specialty drugs. For nonfederal hospitals, clinics, and overall (all sectors), estimates of growth of pharmaceutical expenditures in 2023 were based on a combination of quantitative analyses and expert opinion. Results In 2022, overall pharmaceutical expenditures in the US grew 9.4% compared to 2021, for a total of $633.5 billion. Utilization (a 5.9% increase), price (a 1.7% increase) and new drugs (a 1.8% increase) drove this increase. Adalimumab was the top-selling drug in 2022, followed by semaglutide and apixaban. Drug expenditures were $37.2 billion (a 5.9% decrease) and $116.9 billion (a 10.4% increase) in nonfederal hospitals and clinics, respectively. In clinics, new products and increased utilization growth drove growth, with a small impact from price changes. In nonfederal hospitals, a drop in utilization led to a decrease in expenditures, with price changes and new drugs contributing to growth in spending. Several new drugs that will influence spending have been or are expected to be approved in 2023. Specialty and cancer drugs will continue to drive expenditures along with the evolution of the COVID-19 pandemic. Conclusion For 2023, we expect overall prescription drug spending to rise by 6.0% to 8.0%, whereas in clinics and hospitals we anticipate increases of 8.0% to 10.0% and 1.0% to 3.0%, respectively, compared to 2022. These national estimates of future pharmaceutical expenditure growth may not be representative of any particular health system because of the myriad of local factors that influence actual spending.
εγ-Thalassemia, a New Hemoglobinopathy Category
Oliveira, Jennifer L. , Thompson, Christineil , Saravanaperumal, Siva Arumugam , Koganti, Tejaswi , Jenkinson, Garrett , Hein, Molly S., Kohorst, Mira A. , Hasadsri, Linda , Nguyen, Phuong L., Matern, Dietrich , Kipp, Benjamin R. , Klee, Eric W. , Wieben, Eric D. , Hoyer, James D., Rangan, Aruna , Thompson, Christineil H

Mayo Clinic

Clinical Chemistry | April 22, 2023 | Volume: 69 | Issue: 7 | Pages: 711-717

10.1093/clinchem/hvad038 | PMID 37086467 Get It

Abstract Background Large β-globin gene cluster deletions (hereditary persistence of fetal hemoglobin [Hb] or β-, δβ-, γδβ-, and ϵγδβ-thalassemia), are associated with widely disparate phenotypes, including variable degrees of microcytic anemia and Hb F levels. When present, increased Hb A2 is used as a surrogate marker for β-thalassemia. Notably, ϵγδβ-thalassemias lack the essential regulatory locus control region (LCR) and cause severe transient perinatal anemia but normal newborn screen (NBS) results and Hb A2 levels. Herein, we report a novel deletion of the ϵ, Aγ, Gγ, and ψβ loci with intact LCR, δ-, and β-regions in 2 women and newborn twins. Methods Capillary electrophoresis (CE), high-performance liquid chromatography (HPLC), DNA sequencing, multiplex ligation-dependent probe amplification (MLPA), gap-polymerase chain reaction (gap-PCR), and long-read sequencing (LRS) were performed. Results NBS showed an Hb A > Hb F pattern for both twins. At 20 months, Hb A2 was increased similarly to that in the mother and an unrelated woman. Unexplained microcytosis was absent and the twins lacked severe neonatal anemia. MLPA, LRS, and gap-PCR confirmed a 32 599 base pair deletion of ϵ (HBE1) through ψβ (HBBP1) loci. Conclusions This deletion represents a hemoglobinopathy category with a distinct phenotype that has not been previously described, an ϵγ-thalassemia. Both the NBS Hb A > F pattern and the subsequent increased Hb A2 without microcytosis are unusual. A similar deletion should be considered when this pattern is encountered and appropriate test methods selected for detection. Knowledge of the clinical impact of this new category will improve genetic counselling, with distinction from the severe transient anemia associated with ϵγδβ-thalassemia.
Teaching Video NeuroImages: Acquired focal neuromyotonia in LGI-1 autoimmunity
López‐Chiriboga, A. Sebastian , Matsumoto, Joseph Y., Sorenson, Eric J. , Klein, Christopher J. , McKeon, Andrew

Mayo Clinic

Neurology | April 21, 2023 | Volume: 100 | Issue: 16_supplement_1 | Pages: No page available

10.1212/wnl.0000000000206956 Get It

The Characteristics of Isolated Bulb Celiac Disease in Children
Khan, Muhammad Rehan , Ismail, Yasmine, Swantek, Courtney, Chen, Zongming , Absah, Imad , Behl, Supriya, Chen, Zong-Ming Eric, Behl, Supriya , Swantek, Courtney, Murray, Joseph A.

Mayo Clinic

Journal of Pediatric Gastroenterology and Nutrition | April 21, 2023 | Volume: 77 | Issue: 1 | Pages: 79-85

10.1097/mpg.0000000000003799 | PMID 37084335 Get It

Objectives:Mucosal injury in celiac disease (CD) patients can be patchy, and up to 12% of CD patients can have mucosal changes limited to the duodenal bulb. Hence, recent guidelines recommend obtaining bulb biopsies in addition to distal duodenum. This study aimed to describe a cohort of children with isolated bulb CD and assess the benefit of separating bulb biopsies.Methods:A retrospective chart review between January 2011 and January 2022 at 2 medical centers was conducted. We included children with CD who underwent endoscopy with separated biopsies from the bulb and distal duodenum. A blinded pathologist performed Marsh‐Oberhuber grading on selected cases.Results:We identified 224 CD patients, of which 33 (15%) had histologically confirmed isolated bulb CD. Patients with isolated bulb CD were older at diagnosis (10 vs 8 years; P = 0.03). Median anti‐tissue transglutaminase immunoglobulin A (TTG IgA) level was lower in isolate bulb CD (2.8 vs 16.7 times the upper limit of normal [ULN], P < 0.001). Almost 88% (29/33) of isolated bulb CD patients had an anti‐TTG IgA value of less than 10 times the ULN. Time to anti‐TTG IgA normalization (mean 14 months) was similar between the 2 groups. A pathologist review of diagnostic biopsies could not distinguish between the bulb and distal duodenum biopsies in approximately one‐third of the reviewed samples.Conclusions:Separating bulb from distal duodenum biopsies can be considered during CD diagnosis, particularly in children with anti‐TTG IgA levels less than 10 times the ULN. Larger prospective cohorts are needed to decide whether isolated bulb CD is a unique cohort or an early stage of the conventional CD.
Long‐term quality of life after treatment in sinonasal malignancy: A prospective, multicenter study
Maoz, Sabrina L. , Hwang, Peter H. , Fleseriu, Cara M. , Chan, Erik P., Adappa, Nithin D. , Getz, Anne E., Humphreys, Ian M. , Chang, Eugene H. , Jafari, Aria , Kingdom, Todd T. , Kohanski, Michael A. , Lee, Jivianne K., Lazor, Jillian W. , Nabavizadeh, Ali , Adappa, Nithin D. , Patel, Zara M. , Smith, Timothy L. , Storm, Phillip B. , Suh, Jeffrey D. , Wang, Marilene B. , Sim, Myung‐Shin , Wang, Eric W , Choby, Garret , Kuan, Edward C , Humphreys, Ian M , Jafari, Aria , Nayak, Jayakar V , Patel, Zara , Smith, Timothy L , Snyderman, Carl H , Beswick, Daniel , Hwang, Peter H , Maoz, Sabrina L , Choby, Garret , Chan, Erik, Adappa, Nithin D. , Geltzeiler, Mathew , Le, Christopher H. , Abuzeid, Waleed M. , Lee, Jivianne K., Nayak, Jayakar V. , Pinheiro‐Neto, Carlos , Resnick, Adam , John, Maie A. St. , Beswick, Daniel M.

Mayo Clinic

International Forum of Allergy & Rhinology | April 21, 2023 | Volume: 13 | Issue: 11 | Pages: 2030-2042

10.1002/alr.23171 | PMID 37082883 Get It

AbstractBackgroundQuality of life (QOL) for individuals with sinonasal malignancy (SNM) is significantly under‐studied, yet it is critical for counseling and may impact treatment. In this study we evaluated how patient, treatment, and disease factors impact sinonasal‐specific and generalized QOL using validated metrics in a large cohort over a 5‐year posttreatment time frame.MethodsPatients with SNM who underwent definitive treatment with curative intent were enrolled in a prospective, multisite, longitudinal observational study. QOL was assessed using the 22‐item Sino‐Nasal Outcome Test (SNOT‐22) and University of Washington Quality of Life Questionnaire (UWQOL) instruments at pretreatment baseline and multiple follow‐ups through 5 years posttreatment. Multivariable modeling was used to determine demographic, disease, and treatment factors associated with disease‐specific and generalized physical and social/emotional function QOL.ResultsOne hundred ninety‐four patients with SNM were analyzed. All QOL indices were impaired at pretreatment baseline and improved after treatment. SNOT‐22 scores improved 3 months and UWQOL scores improved 6 to 9 months posttreatment. Patients who underwent open compared with endoscopic tumor resection had worse generalized QOL (p < 0.001), adjusted for factors including T stage. Pterygopalatine fossa (PPF) involvement was associated with worse QOL (SNOT‐22, p < 0.001; UWQOL Physical dimension, p = 0.02). Adjuvant radiation was associated with worse disease‐specific QOL (p = 0.03). Neck dissection was associated with worse generalized physical function QOL (p = 0.01). Positive margins were associated with worse generalized social/emotional function QOL (p = 0.01).ConclusionDisease‐specific and generalized QOL is impaired at baseline in patients with SNM and improves after treatment. Endoscopic resection is associated with better QOL. PPF involvement, adjuvant radiation, neck dissection, and positive margins were associated with worse QOL posttreatment.
Genetic coding variant in complement factor B (CFB) is associated with increased risk for perianal Crohn’s disease and leads to impaired CFB cleavage and phagocytosis
Akhlaghpour, Marzieh, Haritunians, Talin , More, Shyam K., Thomas, Lisa , Stamps, Dalton T., Dube, Shishir, Li, Dalin , Yang, Shaohong, Landers, Carol J., Hamade, Hussein , Murali, Ramachandran , Potdar, Alka A. , Wolf, Andrea J. , Botwin, Gregory J., Khrom, Michelle , Faubion, William A. , Jabrì, Bana , Lira, Sérgio A. , Newberry, Rodney D. , Sandler, Robert S. , Sartor, R. Balfour , Xavier, Ramnik J. , Lazarev, Mark , Rioux, John D. , Silverberg, Mark S. , Zaghiyan, Karen , Fleshner, Phillip , Melmed, Gil , Vasiliauskas, Eric A., Ha, Christina , Rabizadeh, Shervin , Syal, Gaurav , Bonthala, Nirupama , Ziring, David , Targan, Stephan R. , Long, Millie D. , Michelsen, Kathrin S. , Nöthen, Markus M. , Ellinghaus, David , D’Amato, Mauro , Halfvarson, Jonas , Lee, James , Limbergen, Johan Van , Mowat, Craig , Hamade, Hussein , Ananthakrishnan, A N , Lira, Sergio A , Cho, Judy H , Michelsen, Kathrin S , Haritunians, Talin , Ellinghaus, David , D'Amato, Mauro , Nöthen, Markus M , Sandler, Robert S , Melmed, Gil Y , Halfvarson, Jonas , Newberry, Rodney D , Rioux, John D , Mengesha, Emebet , Ananthakrishnan, Ashwin N. , Jabrì, Bana , Brant, Steven R , Duerr, Richard H , Schumm, L. Philip , McGovern, Dermot , Lee, James C.

Mayo Clinic

Gut | April 20, 2023 | Volume: 72 | Issue: 11 | Pages: 2068-2080

10.1136/gutjnl-2023-329689 | PMID 37080587 Get It

Objective Perianal Crohn’s disease (pCD) occurs in up to 40% of patients with CD and is associated with poor quality of life, limited treatment responses and poorly understood aetiology. We performed a genetic association study comparing CD subjects with and without perianal disease and subsequently performed functional follow-up studies for a pCD associated SNP in Complement Factor B ( CFB ). Design Immunochip-based meta-analysis on 4056 pCD and 11 088 patients with CD from three independent cohorts was performed. Serological and clinical variables were analysed by regression analyses. Risk allele of rs4151651 was introduced into human CFB plasmid by site-directed mutagenesis. Binding of recombinant G252 or S252 CFB to C3b and its cleavage was determined in cell-free assays. Macrophage phagocytosis in presence of recombinant CFB or serum from CFB risk, or protective CD or healthy subjects was assessed by flow cytometry. Results Perianal complications were associated with colonic involvement, OmpC and ASCA serology, and serology quartile sum score. We identified a genetic association for pCD (rs4151651), a non-synonymous SNP (G252S) in CFB , in all three cohorts. Recombinant S252 CFB had reduced binding to C3b, its cleavage was impaired, and complement-driven phagocytosis and cytokine secretion were reduced compared with G252 CFB. Serine 252 generates a de novo glycosylation site in CFB. Serum from homozygous risk patients displayed significantly decreased macrophage phagocytosis compared with non-risk serum. Conclusion pCD-associated rs4151651 in CFB is a loss-of-function mutation that impairs its cleavage, activation of alternative complement pathway, and pathogen phagocytosis thus implicating the alternative complement pathway and CFB in pCD aetiology.
Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
Ailawadhi, Sikander , Chen, Zi , Huang, Bo , Paulus, Aneel , Collins, Mary C. , Fu, Lei , Li, Mingyu , Ahmad, Mohammad , Men, Lichuang , Wang, Hengbang , Liang, Eric , Mekala, Divya J. , He, Zhicong , Lasica, Masa , Yannakou, Costas K. , Glass, Laura , Yang, Dajun , Chanan‐Khan, Asher , Fu, Lei Tommy , Davids, Matthew S , Liang, Eric , Mekala, Divya J , He, Zhicong , Lasica, Masa , Yannakou, Costas K , Parrondo, Ricardo D , Glass, Laura , Yang, Dajun , Chanan-Khan, Asher , Zhai, Yifan , Ailawadhi, Sikander , Paulus, Aneel , Davids, Matthew S.

Mayo Clinic

Clinical Cancer Research | April 19, 2023 | Volume: 29 | Issue: 13 | Pages: 2385-2393

10.1158/1078-0432.ccr-22-3321 | PMID 37074726 Get It

Abstract Purpose: This global phase I trial investigated the safety, efficacy, pharmacokinetics, and pharmacodynamics of lisaftoclax (APG-2575), a novel, orally active, potent selective B-cell lymphoma 2 (BCL-2) inhibitor, in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (R/R CLL/SLL) and other hematologic malignancies (HMs). Patients and Methods: Maximum tolerated dose (MTD) and recommended phase II dose were evaluated. Outcome measures were safety and tolerability (primary) and pharmacokinetic variables and antitumor effects (secondary). Pharmacodynamics in patient tumor cells were explored. Results: Among 52 patients receiving lisaftoclax, MTD was not reached. Treatment-emergent adverse events (TEAEs) included diarrhea (48.1%), fatigue (34.6%), nausea (30.8%), anemia and thrombocytopenia (28.8% each), neutropenia (26.9%), constipation (25.0%), vomiting (23.1%), headache (21.2%), peripheral edema and hypokalemia (17.3% each), and arthralgia (15.4%). Grade ≥ 3 hematologic TEAEs included neutropenia (21.2%), thrombocytopenia (13.5%), and anemia (9.6%), none resulting in treatment discontinuation. Clinical pharmacokinetic and pharmacodynamic results demonstrated that lisaftoclax had a limited plasma residence and systemic exposure and elicited rapid clearance of malignant cells. With a median treatment of 15 (range, 6–43) cycles, 14 of 22 efficacy-evaluable patients with R/R CLL/SLL experienced partial responses, for an objective response rate of 63.6% and median time to response of 2 (range, 2–8) cycles. Conclusions: Lisaftoclax was well tolerated, with no evidence of tumor lysis syndrome. Dose-limiting toxicity was not reached at the highest dose level. Lisaftoclax has a unique pharmacokinetic profile compatible with a potentially more convenient daily (vs. weekly) dose ramp-up schedule and induced rapid clinical responses in patients with CLL/SLL, warranting continued clinical investigation.